1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3)

1-acyl-sn-glycerol-3-phosphate acyltransferase gamma (AGPAT3) is an integral membrane acyltransferase enzyme encoded by the AGPAT3 gene in humans[3]. Its primary function is to catalyze the second step of *de novo* phospholipid biosynthesis—specifically, the conversion of lysophosphatidic acid (LPA) to phosphatidic acid (PA)[1][3]. AGPAT3 is localized to the endoplasmic reticulum, nuclear envelope, and Golgi apparatus[2][1]. The protein contains two transmembrane domains and four conserved motifs critical for its phospholipid-transfer function[2]. AGPAT3 displays substrate specificity, preferring LPA with oleic acid and oleoyl-CoA as donor, but also can act on other lysophospholipids under specific conditions[1]. Expression is ubiquitous across human tissues, with varying levels of mRNA[1]. AGPAT3 is involved in the biosynthesis of membrane phospholipids, which are essential for cell structure, signaling, and energy metabolism. Alterations in its activity may contribute to metabolic diseases including cancer, as lipid metabolism impacts cell proliferation and survival[1][3]. No interacting drugs, clinical biomarkers, or specific safety concerns are currently documented in the sourced literature.

Other names

AGPAT3LPAAT3LPAAT-gammaLPLAT31-acylglycerol-3-phosphate O-acyltransferase 31-AGPAT 3lysophosphatidic acid acyltransferase gammalysophospholipid acyltransferase 3

Drugs targeting this molecule would typically inhibit or modulate its acyltransferase activity, altering LPA to PA conversion rates